Navigation Links
EntreMed to Present at the Rodman and Renshaw 10th Annual Healthcare Conference
Date:11/7/2008

ROCKVILLE, Md., Nov. 7 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that James S. Burns, President and Chief Executive Officer, will present a Company update at the Rodman and Renshaw 10th Annual Healthcare Conference, which is being held November 10-12, 2008 at the New York Palace Hotel in New York, NY. Mr. Burns' presentation is scheduled for Tuesday, November 11, 2008 at 2:25 p.m. (local time).

Mr. Burns' presentation will be web cast and, as previously announced, will serve as the Company's third quarter 2008 update. The presentation can be accessed through the Company's web site at http://www.entremed.com. An archive will be available on the web site for approximately 90 days.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-2076, a selective angiogenic kinase inhibitor, and ENMD-1198, a novel antimitotic agent are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation, cell signaling and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. EntreMed Receives Deloitte Technology Fast 50 Award
2. EntreMed to Present at the Bio 2007 Investor Forum
3. EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study
4. EntreMed to Present at the Rodman and Renshaw 9th Annual Healthcare Conference
5. EntreMed Reports Third Quarter 2007 Financial Results
6. EntreMed Presents Results for ENMD-1198 and Vincristine in Preclinical Leukemia Models
7. EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis
8. EntreMed to Present at the Jesup & Lamont Emerging Growth Stock Conference
9. Dr. Ronald E. Cape to Retire from EntreMed Board of Directors
10. EntreMed Reports First Quarter 2008 Financial Results
11. EntreMed to Present at The Rodman and Renshaw 5th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... Raton, Fl (PRWEB) , ... August 30, 2015 , ... ... to have beneficial effects as sleep aids and calming remedies, which help to improve ... the result of a great deal of research in the field of regenerative medicine ...
(Date:8/29/2015)... ... August 30, 2015 , ... Rio Salado College President Chris Bustamante ... Vice President of Strategic Initiatives and Information Services. O’Shea, who has served Rio Salado ... its reach and impact through innovative technologies and strategies. , “I am very proud ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... support and protection against dribbled urine and sweat. "In order to prevent these ... , The EASY ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides optimal support for a ...
(Date:8/29/2015)... Aliso Viejo, CA (PRWEB) , ... August 29, 2015 , ... ... Cut Pro X . Each preset contains 15 seconds of unique footage that users ... presets that rise, fall, zoom, attract and more. Users can customize color, brightness, scale, ...
(Date:8/28/2015)... (PRWEB) , ... August 29, 2015 , ... Rio ... higher learning and the student experience as part of the EDUCAUSE - Next Generation ... Foundation . , This is the third Breakthrough Models Incubator hosted by ...
Breaking Medicine News(10 mins):Health News:Creative Medical Health’s Natural Rest® Now Available on ReCreative Medical Health’s Natural Rest® Now Available on RevNutrition.com 2Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4
... strikes a chord ... with frustrated women, SALT LAKE CITY, March 12 ... undertones., "I love the commercial because sometimes my husband remembers to ... make any,difference," says a customer service rep (who wishes to remain anonymous),at ...
... in U.S. may block brain receptor among some users ... weight-loss drug rimonabant has been associated with troubling psychiatric ... why. , A receptor in the brain called TRPV1, ... blocked by large doses of rimonabant (Acomplia), resulting in ...
... IVF Success, NEWBURGH, N.Y., March 12 ... Mount Sinai Hospital, is proud to introduce,premier fertility ... of,Reproductive Endocrinologist Jeffrey Klein, M.D. to its medical ... Westchester division of,Reproductive Medicine Associates (RMA) of New ...
... Institutets Board of Research confers the title honorary doctor ... have promoted activities carried out at the university. This ... conferred. The ceremony will take place on Friday 9 ... honorary doctors will receive their doctoral hats, diplomas and ...
... that restores a missing liver enzyme in test animals ... in humans, according to Duke University Medical Center researchers. ... disease type Ia (GSD-Ia), cant make an enzyme that ... that all cells use for energy. Without treatment, their ...
... Founders donating stock to establish corporate foundation; Community ... program helps care for the aging in Bay ... Caring.com is pleased to,announce its participation as the ... dedicated to engaging high-growth,companies in corporate citizenship and ...
Cached Medicine News:Health News:An Important Message to Anyone Taking Viagra ... From The Women Who Love You ... and Zoller Labs 2Health News:Possible Reason for Rimonabant's Side Effects Discovered 2Health News:Possible Reason for Rimonabant's Side Effects Discovered 3Health News:SLCH Brings Infertility Specialist to Region 2Health News:3 new honorary doctors at Karolinska Institutet 2Health News:Gene therapy could save kids from a lifetime of eating cornstarch 2Health News:Gene therapy could save kids from a lifetime of eating cornstarch 3Health News:Caring.com Joins Entrepreneurs Foundation as 200th Member 2
(Date:8/27/2015)... Calif. , Aug. 27, 2015 ... milestone in the commercial development of the company,s ... The Smart Oxygen device, being developed by ieCrowd,s ... to a patient,s changing demand for oxygen based ... the 510 (k) submission for the Smart Oxygen ...
(Date:8/27/2015)... , Aug. 27, 2015  Eli Lilly and Company ... Global Healthcare Conference on Thursday, September 17, 2015. ... of Lilly Oncology and Richard Gaynor , M.D., ... for Lilly Oncology, will participate in a fireside chat ... A live audio webcast will be available on the ...
(Date:8/27/2015)... Aug. 27, 2015   Women Grow , the fastest-growing professional ... partnering with the Cannabis World Congress & Business Exposition ... produce 15 business-focused educational sessions. CWCBExpo in LA will take ... Convention Center in Los Angeles, CA ... West Coast for the marijuana industry. The Women ...
Breaking Medicine Technology:Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 4Lilly to Participate in Morgan Stanley Global Healthcare Conference 2Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 2Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 3Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 4
... NKTR ) today announced positive results from ... study evaluating single-agent NKTR-102 in women with platinum-resistant/refractory ovarian ... with prior Doxil® (pegylated liposomal doxorubicin or PLD) treatment ... criteria (response by tumor imaging) or Gynecologic Cancer InterGroup ...
... CHICAGO and SAN FRANCISCO, June 4, 2011 ... announced positive results from a Phase 2 clinical ... third-line treatment in patients with metastatic breast cancer ... Meeting (ASCO).  NKTR-102, a next-generation topoisomerase I inhibitor, ...
Cached Medicine Technology:NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 2NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 3NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 4NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 5NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 6NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 7NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 8NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting 2NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting 3NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting 4NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting 5NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting 6NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting 7NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting 8NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting 9
200 L, Racked, Filtered, Pre-sterilized, 96 tips/rack Recommended for 20, 25, 50, 100 and 200 L pipettes. Can also be used with 300 L pipettes when pipetting 200 L or less....
... aerosol contamination, which causes ... PCR. Hydrophobic, nonwicking and ... can pass through these ... contrast to tips with ...
Diamond Filter Tips play a critical role in preventing aerosol-borne contamination. Also available sterilized (no need to autoclave) and certified free of detectable RNase, DNase, DNA, RNA, and prote...
... Filters are ideal for PCR ... for any work where aerosol ... designed for pipetting DNA/RNA solutions, ... other. For applications requiring absolute ...
Medicine Products: